Pancreatic Cancer Research

ResearcherJiangnan UniversityActive in the last 2 years

Yuanlong Gu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-8284-1580; OpenAlex author ID A5060582300. Sources: OpenAlex.

Their work

Papers
8 (first author 1, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
18
Papers, trials and grants by year

2014: 1 paper · 2015: none · 2016: none · 2017: 1 paper · 2018: none · 2019: none · 2020: 1 paper · 2021: 2 papers · 2022: 1 paper · 2023: 1 paper · 2024: none · 2025: 1 paper

Papers 8

  1. Diagnostic methods for pancreatic cancer and their clinical applications (Review). Co-author DOI 10.3892/ol.2025.15116↗
  2. Diagnostic value of combining preoperative inflammatory markers ratios with CA199 for patients with early-stage pancreatic cancer. Co-author DOI 10.1186/s12885-023-10653-4↗
  3. Serum exosomal and serum glypican-1 are associated with early recurrence of pancreatic ductal adenocarcinoma. Co-author DOI 10.3389/fonc.2022.992929↗
  4. ACTR3 promotes cell migration and invasion by inducing epithelial mesenchymal transition in pancreatic ductal adenocarcinoma. Last author DOI 10.21037/jgo-21-609↗
  5. NEAT1/miR-101-dependent Up-regulation of DNA-PKcs Enhances Malignant Behaviors of Pancreatic Ductal Adenocarcinoma Cells. Last author DOI 10.7150/jca.58824↗
  6. LINC01559 accelerates pancreatic cancer cell proliferation and migration through YAP-mediated pathway. Co-author DOI 10.1002/jcp.29288↗
  7. micorRNA-101 silences DNA-PKcs and sensitizes pancreatic cancer cells to gemcitabine. Last author DOI 10.1016/j.bbrc.2016.12.074↗
  8. DNA-PKcs is important for Akt activation and gemcitabine resistance in PANC-1 pancreatic cancer cells. First author DOI 10.1016/j.bbrc.2014.08.059↗

Closest collaborators

The 18 strongest of 18 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Juan Zhao · 1 shared paper, 2025 · strength 0.33
  2. Xiaoyi Huang · 1 shared paper, 2025 · strength 0.33
  3. Linyou Wang · 1 shared paper, 2025 · strength 0.33
  4. Hao Hu · 2 shared papers, 2021 · strength 0.32
  5. Changjie Lou · 2 shared papers, 2020–2023 · strength 0.29
  6. Peiyuan Cai · 1 shared paper, 2023 · strength 0.18
  7. Juan Zhao · 1 shared paper, 2023 · strength 0.18
  8. Shuo Zhang · 1 shared paper, 2021 · strength 0.16
  9. Yuzheng Xue · 1 shared paper, 2021 · strength 0.16
  10. Juan Zhao · 1 shared paper, 2022 · strength 0.15
  11. Xiaoyi Huang · 1 shared paper, 2022 · strength 0.15
  12. Hao Hu · 2 shared papers, 2014–2017 · strength 0.13
  13. Zhiwei Li · 1 shared paper, 2020 · strength 0.11
  14. Yanqiao Zhang · 1 shared paper, 2020 · strength 0.11
  15. Yuan Ming He · 1 shared paper, 2017 · strength 0.08
  16. Yandong Wang · 1 shared paper, 2017 · strength 0.08
  17. Congyuan Zhu · 1 shared paper, 2014 · strength 0.05
  18. Jian-Ping Li · 1 shared paper, 2014 · strength 0.05

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.